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Abstract
Background: Atrial fibrillation is the most common arrhythmia of the heart with a prevalence of approximately 2%
in the western world. Atrial flutter, another arrhythmia, occurs less often with an incidence of approximately 200,000
new patients per year in the USA. Patients with atrial fibrillation and atrial flutter have an increased risk of death
and morbidities. The management of atrial fibrillation and atrial flutter is often based on interventions aiming at
either a rhythm control strategy or a rate control strategy. The evidence on the comparable effects of these
strategies is unclear. This protocol for a systematic review aims at identifying the best overall treatment strategy for
atrial fibrillation and atrial flutter.
Methods: This protocol for a systematic review was performed following the recommendations of the Cochrane
Collaboration and the eight-step assessment procedure suggested by Jakobsen and colleagues. We plan to include
all relevant randomised clinical trials assessing the effects of any rhythm control strategy versus any rate control
strategy. We plan to search the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, LILACS,
Science Citation Index Expanded on Web of Science, and BIOSIS to identify relevant trials. Any eligible trial will be
assessed and classified as either high risk of bias or low risk of bias, and our conclusions will be based on trials with
low risk of bias. The analyses of the extracted data will be performed using Review Manager 5 and Trial Sequential
Analysis. For both our primary and secondary outcomes, we will create a ‘Summary of Findings’ table and use
GRADE assessment to assess the quality of the evidence.
Discussion: The results of this systematic review have the potential to benefit thousands of patients worldwide as
well as healthcare systems and healthcare economy.
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Background
Atrial fibrillation is the most common arrhythmia of the
heart with a prevalence of approximately 2% in the west-
ern world [1, 2]. Atrial flutter, another arrhythmia,
occurs less often with an incidence of approximately
200,000 new patients per year in the USA [3]. The
prevalence of both atrial fibrillation and atrial flutter are
increasing possibly because of a greater life expectancy
in the general population, an increased prevalence of
risk factors for atrial fibrillation and atrial flutter, and an
improved ability to suspect and diagnose the arrhyth-
mias [1, 4, 5]. Atrial fibrillation and atrial flutter are
associated with an increased risk of death and morbid-
ities [6–12]. The risks of both cerebral stroke and heart
failure are increased nearly fivefold in patients with atrial
fibrillation and atrial flutter, and an estimated 20% of
every stroke may be due to atrial fibrillation [6–11].
Atrial fibrillation and atrial flutter also have a significant
impact on healthcare costs and account for approxi-
mately 1% of the National Health Service budget in the
UK and approximately 26 billion dollars of annual
expenses in the USA [13, 14].
Definition and classification
The atriums of the heart receive blood returning from
the body and pump it further ahead to the ventricles.
Atrial fibrillation and atrial flutter are defined as abnor-
mal heart rhythms that arise from improper electrical
activity of the heart which lead to ineffective mechanical
contraction [15–17]. The ineffective mechanical contrac-
tion stresses the muscle cells of the heart which over
time may cause heart failure [18, 19]. Persistent rapid
rates can also cause or worsen a tachycardia-mediated
cardiomyopathy [20].
Atrial fibrillation and atrial flutter can be asymptom-
atic or lead to symptoms such as palpitations, dyspnoea,
and dizziness [21]. Atrial fibrillation may be diagnosed
using an electrocardiogram as (1) irregular R-R intervals
(when atrioventricular conduction is present), (2)
absence of distinct repeating P-waves, and/or (3) irregu-
lar atrial activity [16, 17]. Atrial flutter may be diagnosed
using an electrocardiogram as characteristic flutter
waves (F-waves) at a regular atrial rate of 250 to 350
beats per minute. The flutter waves may resemble P-
waves or have a ‘saw-tooth’ shape [22].
Atrial fibrillation may either be non-valvular or valvu-
lar, where the latter form is characterised by rheumatic
mitral stenosis, mechanical heart valve, tissue heart
valve, or mitral valve repair [1]. However, the definition
of the terms non-valvular and valvular lacks consistency
in both trials and guidelines [23, 24]. A paper has pro-
posed a new term ‘mechanical and rheumatic mitral
valvular atrial fibrillation’, as they report that only
mechanical valves and mitral stenosis have special needs
in regard to antithrombotic treatment [24].
The development of atrial fibrillation is associated with
various risk factors, e.g. ageing, obesity, smoking, hyper-
tension, diabetes, and other cardiac diseases (valvular or
other structural heart diseases) [17, 25]. The develop-
ment of atrial flutter is presumably associated with pro-
longed PR interval and some of the same risk factors as
atrial fibrillation [8]. However, it has not been demon-
strated that atrial flutter is associated with either obesity,
diabetes, hypertension, or valvular heart disease [8]. Both
atrial fibrillation and atrial flutter may also occur in
patients with no risk factors (so called lone atrial fibrilla-
tion or lone atrial flutter) [3].
Based on the duration of the arrhythmia, atrial fibrilla-
tion may be divided into five different forms [15–17]:
 Recent-onset atrial fibrillation
 Paroxysmal atrial fibrillation
 Persistent atrial fibrillation
 Long-standing persistent atrial fibrillation
 Permanent atrial fibrillation
Based on the re-entrant circuit, atrial flutter may be
divided into two different forms:
 Typical atrial flutter is a macro-reentrant atrial
tachycardia that can be subdivided based on the
rotation of the circuit to counterclockwise atrial
flutter (90% of patients) or clockwise atrial flutter
(10% of patients) [26].
 Atypical atrial flutter is defined as any atrial
tachycardia with an ECG pattern of continuous
undulation of the atrial complex, different from
typical atrial flutter, at a rate of ≥240 beats per
minute [26].
Pathophysiology
The pathogenesis of atrial fibrillation is thought to be an
interaction between a trigger for initiation and an abnor-
mal tissue substrate for maintenance [25].
The trigger for initiation is often a rapidly firing focus
most often located in the left atrium and the proximal
parts of the pulmonary veins [27]. The abnormal tissue
substrate for maintenance is often a result of an under-
lying heart disease like coronary heart disease, valvular
heart disease, cardiomyopathies, or heart failure [16]. The
pathogenesis of the abnormal tissue substrate is induced
by inflammation [28], fibrosis [29], or hypertrophy [30].
Electric remodelling, such as refractory period short-
ening, occurs after a period of continuous atrial fibrilla-
tion that further facilitate atrial fibrillation, i.e. atrial
fibrillation leads to atrial fibrillation [30, 31]. Neverthe-
less, the electric remodelling is often reversible if sinus
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rhythm is restored, though it can become permanent if
atrial fibrillation persists [31].
Atrial flutter is classified as a macro-reentrant tachycar-
dia. The macro-reentrant tachycardia occurs when an
electrical impulse recurrently moves in a self-perpetuating
circuit within the heart, rather than moving from one end
of the heart to the other and terminating [26].
Antithrombotic treatment
As mentioned in the ‘Background’ section, the risk of
stroke is increased nearly fivefold in patients with atrial
fibrillation and atrial flutter [10]. Antithrombotic treat-
ment is necessary to reduce the risk of stroke in high-
risk patients with atrial fibrillation and atrial flutter,
regardless of the management strategy [16]. The risk of
stroke in patients with atrial fibrillation and atrial flutter
can be estimated by the CHA2DS2-VASc score [32],
while the risk of bleeding can be estimated by the HAS-
BLED score [33]. Combined, these may help the phys-
ician determine the patient’s need for antithrombotic
treatment [16].
Antithrombotic drugs aim at reducing the formation
of thrombi by affecting different clotting processes.
Depending on the mechanism, the drugs are divided into
either anticoagulants or antiplatelet drugs. The classifi-
cation, mechanism, and examples of anticoagulants and
antiplatelet drugs are summarised in Table 1.
The comparative efficacy and safety between anticoag-
ulants and antiplatelet drugs has been assessed. Two
systematic reviews have shown that both warfarin and
apixaban are superior to antiplatelet drugs for prevent-
ing stroke, with a similar rate of major bleeding and
intracranial haemorrhage [34, 35].
The comparative efficacy and safety between warfarin
and non-vitamin K-dependent antagonist has been
assessed. Ruff et al. showed in a systematic review that
the non-vitamin K-dependent antagonists compared
with warfarin significantly reduced the risk of all-cause
mortality by 10%, stroke by 19%, and intracranial haem-
orrhage by 52%. However, the risk of gastrointestinal
bleeding was increased by 25% by the non-vitamin K-
dependent antagonists [36].
Description of the interventions
Two different overall intervention strategies may be used
for atrial fibrillation and atrial flutter—a rhythm control
strategy and a rate control strategy [16]. The overall
aims of a rhythm control strategy and a rate control
strategy differ. A rhythm control strategy aims at obtain-
ing and maintaining sinus rhythm, while a rate control
strategy is an overall term for a strategy where the short-
and long-term aim is to lower the ventricular frequency
[25]. Patients that receive rhythm control will often need
some kind of rate control until they have obtained sinus
rhythm.
The interventions used for both rhythm- and rate
control strategies encompass both drugs and ablation. In
addition, electrical cardioversion is also used for rhythm
control.
The drugs used in both a rhythm control strategy and
a rate control strategy are classified according to two
different classifications: the Vaughan Williams classifica-
tion and the Sicilian Gambit classification.
 The Vaughan Williams classification classifies the
drugs in five different classes according to their
general effect. Class I and III drugs are mainly used
for a rhythm control strategy; class II and IV drugs
are mainly used for a rate control strategy; and class
V drugs are used for both strategies [37]. The
Vaughan Williams classification is summarised in
Table 2.
 The Sicilian Gambit classification places a greater
approach on the underlying mechanism of the drugs
and classifies each drug according to the effects on
bio-cellular channels, receptors, and pumps. We will
not describe this classification in detail but refer to
the work by the European Society of Cardiology [38].
We will in this systematic review use the Vaughan
Williams classification which is the most commonly
used classification.
Rhythm control strategies
A rhythm control strategy typically uses medical rhythm
control or electrical cardioversion as the main rhythm
Table 1 The classification, mechanism, and examples of
anticoagulants and antiplatelet drugs
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control intervention. If they do not work, catheter
ablation or surgical ablation may be considered [39].
Medical rhythm control
Medical rhythm control involves antiarrhythmic drugs
and is used for either (1) cardioversion of atrial fibrilla-
tion or atrial flutter to sinus rhythm or (2) maintenance
of sinus rhythm [16].
The main drugs used for medical cardioversion of
atrial fibrillation and atrial flutter are flecainide (class
Ic), propafenone (class Ic), dofetilide (class III), and ami-
odarone (class III) [16]. A systematic review showed that
intravenous vernakalant (class III), intravenous propafe-
none (class Ic), and both oral and intravenous flecainide
(class Ic) seemed to be significantly more effective than
placebo at restoring sinus rhythm within 2 h of adminis-
tration in recent-onset atrial fibrillation [40]. When they
analysed for successful cardioversion within 8–24 h, oral
amiodarone (class III), oral flecainide (Ic), and both oral
and intravenous propafenone (class Ic) seemed to be
significantly more effective than placebo [40].
The main drugs used for maintenance of sinus rhythm
are amiodarone (class III), dofetilide (class III), dronedar-
one (class III), flecainide (class Ic), propafenone (class
Ic), beta blockers (class II), and sotalol (class III) [16].
Lafuente-Lafuente et al. showed in a Cochrane review
that drugs belonging to class Ia (disopyramide and
quinidine), class Ic (flecainide and propafenone), class II
(metoprolol), and class III (amiodarone, dofetilide, dro-
nedarone, and sotalol) were moderately effective in
maintaining sinus rhythm compared with patients not
receiving antiarrhythmic drugs (56). Nonetheless, all
drugs were associated with adverse events, including
proarrhythmia (new or more frequent occurrence of
pre-existing arrhythmias) [41]. Treatment with quinidine
(class Ia), disopyramide (class Ia), or sotalol (class III)
compared with not receiving antiarrhythmic drugs was
associated with higher risks of all-cause mortality and
serious adverse events [41]. In regard to class Ic drugs
(flecainide and propafenone), no increased risk of
mortality was found. However, as the data obtained on
mortality with flecainide (class Ic) and propafenone
(class Ic) seemed sparse, the authors concluded that the
result was uncertain [41]. Guidelines recommend that
flecainide (class Ic) and propafenone (class Ic) should
only be used in patients without ischaemic heart disease
or heart failure [16, 42]. This is based on a randomised
trial from 1989, the Cardiac Arrhythmia Suppression
Trial (CAST), that compared antiarrhythmic drug ther-
apy with placebo in patients with asymptomatic or
mildly symptomatic ventricular arrhythmia (six or more
ventricular premature beats per hour) after myocardial
infarction [43]. The trial showed an increased risk of
mortality and sudden cardiac death caused by ventricu-
lar arrhythmias in the patients receiving encainide (class
Ic) and flecainide (class Ic) compared with placebo [43].
In several systematic reviews, amiodarone (class III)
was shown to be better than class I (flecainide, propafe-
none, disopyramide, and quinidine) and other class III
drugs (sotalol, dofetilide, and dronedarone) at maintain-
ing sinus rhythm [41, 44–46]. However, in one system-
atic review, amiodarone (class III) was shown to induce
a higher number of adverse events [46].
Electrical cardioversion rhythm control
Electrical cardioversion is a non-invasive procedure that
uses electrical shock to convert atrial fibrillation and
atrial flutter (or other arrhythmias) into sinus rhythm
[16]. Current evidence supports the use of electrical
cardioversion with biphasic waveforms with an intensity
of 200 J for atrial fibrillation, as the proportion of
success is 91 to 94% [47–49]. The monophasic waveform
requires intensity up to 360 J to work, and the propor-
tion of success is 79 to 85% [47–49]. For atrial flutter,
evidence supports the use of biphasic waveforms with an
intensity of 50 to 100 J [50, 51]. It has been shown that
longer duration of atrial fibrillation was inversely associ-
ated with cardioversion proportions [52, 53]. To enhance
Table 2 The Vaughan Williams classification
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the effectiveness of the procedure, antiarrhythmic drugs,
such as amiodarone (class III), flecainide (class Ic), ibuti-
lide (class Ic), propafenone (class Ic), and sotalol (class
III), can be used [54].
Ablation procedures for rhythm control
Two different ablation procedures may be used for
rhythm control in patients with atrial fibrillation and
atrial flutter—catheter ablation or surgical ablation. Both
procedures do not involve controlling the heart rate but
aim at obtaining sinus rhythm.
Catheter ablation may be indicated in patients with
paroxysmal, persistent, or long-standing persistent atrial
fibrillation or atrial flutter that is refractory or intolerant
to medical rhythm control [15]. Catheter ablation of
atrial fibrillation is mostly performed in the left atrium,
usually entering via the vena femoralis, vena jugularis
interna, or vena subclavia. In the left atrium, a series of
lesions are created, and the lesions are thought either to
eliminate possible triggers originating from the pulmon-
ary veins or to modify the substrate that maintains the
atrial fibrillation [15]. Catheter ablation may also be in-
dicated in patients with typical atrial flutter where the le-
sions caused by catheter ablation are thought to
interrupt the macro-reentrant circuit maintaining the
atrial flutter [55]. The main technique for either atrial
fibrillation or atrial flutter is radiofrequency ablation that
achieves myocardial necrosis through tissue heating [15].
In an observational study, the risk of major complica-
tions (e.g. death, tamponade, total femoral pseudoaneur-
ysm, or transient ischemic attack) after catheter ablation
was found to be 4.5% based on 20,825 procedures [56].
Surgical ablation is performed doing a Cox-Maze pro-
cedure by open-heart surgery or a less-invasive right
mini thoracotomy [57]. A Cox-Maze procedure is done
by creating a number of surgical lesions in the left and
right atrium in order to form scar tissue. The scar tissue
inhibits the conduction of electricity, consequently
disrupting the abnormal electrical impulses [58]. The
procedure is most often done concomitantly with other
cardiac surgery than as a lone procedure [57]. A rando-
mised clinical trial compared surgical ablation with no
surgical ablation during mitral-valve surgery and showed
significantly higher conversion rates in the surgical abla-
tion group [59]. The risk of mortality was similar to both
groups. However, there was a significantly higher rate of
permanent pacemaker implantation in the surgical abla-
tion group than in the no surgical ablation group [59].
Rate control strategies
Medical rate control
The drugs used for rate control in atrial fibrillation and
atrial flutter are mainly beta blockers (class II), non-
dihydropyridine calcium channel blockers (class IV), and
digoxin (class V) [16, 22]. All three types of drugs work by
lowering the heart rate which might consequently prevent
excessive tachycardia and limit symptoms. Lowering the
heart rate might theoretically prevent the development of
heart failure and tachycardia-mediated cardiomyopathy [18,
20, 60]. An observational study compared rate control with
no rate control and showed lower risk of mortality in the pa-
tients receiving beta blockers (class II) or non-
dihydropyridine calcium channel blockers (class IV). In con-
trast, the patients receiving digoxin (class V) seemed to have
a higher risk of mortality [61]. A systematic review com-
pared rate control interventions with placebo and showed
that selective beta blockers (class II), verapamil (class IV),
diltiazem (class IV), and partial digoxin (class V) were better
than placebo at lowering the heart rate [62]. According to
guidelines, beta blockers (class II) or non-dihydropyridine
calcium channel blockers (class IV) are first-line therapy,
while digoxin (class V) may be combined with one of them
if they alone are insufficient to control the heart rate [16].
The Atrial Fibrillation Follow-up Investigation of Rhythm
Management (AFFIRM) trial showed that beta-blockers
(class II) (with or without digoxin (class V)) achieved rate
control (rest ≤80 beats/min) in 70% of the patients com-
pared with 54% for non-dihydropyridine calcium channel
blockers (class IV) (with or without digoxin (class V)) and
58% for digoxin (class V) (used without beta-blockers (class
II) or non-dihydropyridine calcium channel blockers (class
IV)) [63]. Amiodarone (class III) may also control the heart
rate, as it exhibits beta and calcium channel blockade in
addition to its antiarrhythmic activity. However, amiodarone
(class III) has extensive non-cardiac adverse events and is
only used if other rate control drugs are not effective
enough, not well tolerated, or contraindicated [16]. Accord-
ing to guidelines, physicians should consider the patient’s
degree of symptoms, haemodynamic status, presence or ab-
sence of heart failure, and comorbidities when choosing
which rate control intervention to use [16].
During recent years, observational studies have com-
pared digoxin versus no digoxin in patients with atrial
fibrillation or atrial flutter and showed conflicting results
[64–68]. Some studies have shown that digoxin seemed to
increase the risk of all-cause mortality regardless of con-
comitant heart failure [64, 65], while others did not show
any difference between the compared groups [66–68].
Nonetheless, guidelines recommend using digoxin as the
primary drug for rate control in patients with atrial fibril-
lation or atrial flutter who have concomitant heart failure
and reduced ejection fraction. Digoxin is also recom-
mended for acute rate control in patients with preserved
ejection fraction [16, 42, 69].
Ablation procedures for rate control
Atrioventricular node ablation procedure is a rare but
highly effective procedure that controls the ventricular
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heart rate with the help of a pacemaker [70]. The
procedure is done by ablation of the atrioventricular
node via assess from vena femoralis dexter, consequently
cancelling all electrical impulses from the atriums to the
ventricles. Hence, the procedure induces complete atrio-
ventricular block and permanent pacing is necessary
[71]. The procedure does not involve rhythm control,
and atrial fibrillation or atrial flutter is still present after
the procedure. The atrioventricular node ablation pro-
cedure primarily benefits patients with atrial fibrillation
or atrial flutter who have symptoms refractory to med-
ical rate control [70].
Why is it important to do this review?
Atrial fibrillation and atrial flutter are the most common
arrhythmias of the heart and are associated with an
increased risk of death and morbidities [1–3, 6–12]. The
treatment of atrial fibrillation and atrial flutter is based
on two overall treatment strategies—a rhythm control
strategy and a rate control strategy [16].
Several meta-analyses of randomised trials have com-
pared rhythm control strategies with rate control strat-
egies in patients with atrial fibrillation or atrial flutter
[72–75]. Cordina et al. from 2005 included 2 trials with
4312 participants [73]; Caldeira et al. from 2012 included
8 trials with 7499 participants [75]; Chatterjee et al. from
2013 included 10 trials with 7867 participants [74]; and
Al-Khatib et al. from 2014 included 16 trials with 7608
participants [72]. None of the reviews showed any differ-
ence in effects of any of the strategies on all-cause death
and other patient-centred clinical outcomes. However,
Chatterjee et al. showed lower risk of all-cause mortality
in patients younger than 65 years in the rhythm control
group compared with the rate control group [74]. Cor-
dina et al. showed significantly higher rates of adverse
events in the rhythm control group compared with the
rate control group [73].
No former review comparing rhythm control strategies
with rate control strategies has taken into account both
risks of systematic errors and risks of random errors
(Cochrane methodology, Trial Sequential Analysis, and
the Grades of Recommendation, Assessment, Develop-
ment, and Evaluation (GRADE) assessment) [76–79].
Therefore, it is still unclear whether a rhythm control
strategy or a rate control strategy is the best treatment
strategy in patients with atrial fibrillation and atrial flut-
ter. In the present systematic review, we will collect and
present current evidence of rhythm control versus rate
control for atrial fibrillation and atrial flutter.
Objective
The objective of the study is to assess the beneficial and
harmful effects of rhythm control strategies versus rate
control strategies for atrial fibrillation and atrial flutter.
Methods
This systematic review protocol has been developed based
on Preferred Reporting Items for Systematic Reviews and
Meta-Analysis Protocols (PRISMA-P) guidelines for
reporting systematic reviews evaluating healthcare inter-
ventions [80, 81]. A PRISMA-P checklist file is attached
(Additional file 1).
Criteria for considering studies for this review
Types of studies
Randomised clinical trials irrespective of trial design,
setting, publication status, publication year, and lan-
guage. We will not include quasi-randomised trials and
observational studies for the assessments of harms. We
are aware that this is a limitation of our review.
Types of participants
Patients with atrial fibrillation or atrial flutter. We will
accept the definitions used by the trialists. Patients will
be included irrespective of age, sex, and comorbidities.
Types of interventions
Rhythm control group: we will accept any type of
rhythm control strategy, i.e. any intervention where the
overall aim is to convert the atrial fibrillation or atrial
flutter to sinus rhythm. Treatment elements of the
rhythm control strategy could for example be flecainide,
propafenone, dofetilide, amiodarone, dronedarone, sota-
lol, or electrical cardioversion (all irrespective of dose,
rout of administration, and duration). We will accept if
the rhythm control strategy also includes rate control in-
terventions as part of treatment, but the overall aim
(short or long term) has to be to obtain sinus rhythm.
Rate control group: we will accept any type of rate con-
trol strategy, i.e. any intervention where the overall aim is
to control the heart rate and the focus is not to convert
the atrial fibrillation or atrial flutter to sinus rhythm.
Treatment elements of the rate control strategy could for
example be beta blockers, non-dihydropyridine calcium
channel blockers, digoxin, or amiodarone (all irrespective
of dose, route of administration, and duration).
We will accept any type of co-intervention when such
co-intervention is intended to be delivered similar to the
rhythm control group and the rate control group.
Types of outcome measures
We will for all outcomes use the trial results reported at
maximal follow-up. However, if the trialists report
results at multiple time points, we will primarily use the
results reported at the time point closest to 24 months.
Primary outcomes
1. All-cause mortality.
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2. Serious adverse events. We will define a serious
adverse event as any untoward medical occurrence
that resulted in death, was life-threatening, required
hospitalisation or prolongation of existing
hospitalisation, and resulted in persistent or
significant disability or jeopardised the patient [82].
3. Quality of life measured on any valid scale.
Secondary outcomes
1. Stroke (as defined by the trialists)
2. Ejection fraction (continuous outcome)
All outcomes, except quality of life and ejection fraction,
will be analysed as proportions of participants in each
group.
Search methods for identification of studies
Electronic searches
We will search the Cochrane Central Register of Con-
trolled Trials (CENTRAL), Medical Literature Analysis
and Retrieval System Online (MEDLINE), Excerpta Med-
ica database (EMBASE), Latin American and Caribbean
Health Sciences Literature (LILACS), Science Citation
Index Expanded on Web of Science, and BIOSIS in order
to identify relevant trials. The preliminary search strategy
for MEDLINE (Ovid) is given in Additional file 2.
We will search all databases from their inception to
the present.
Searching other resources
The reference lists of relevant publications will be checked
for any unidentified randomised trials. We will contact
authors of included studies, and major pharmaceutical
companies, by email asking for unpublished randomised
trials. Further, we will search for ongoing trials on:
 ClinicalTrials.gov (www.clinicaltrials.gov)
 Google Scholar (https://scholar.google.dk/)
 The Turning Research into Practice (TRIP) Database
(https://www.tripdatabase.com/)
 European Medicines Agency (EMA) (http://
www.ema.europa.eu/ema/)
 United States Food and Drug Administration (FDA)
(www.fda.gov)
 China Food and Drug Administration (CFDA)
(http://eng.sfda.gov.cn/WS03/CL0755/)





 The World Health Organization (WHO)
International Clinical Trials Registry Platform
(ICTRP) search portal (http://apps.who.int/
trialsearch/)
Additionally, we will handsearch conference abstracts
from cardiology conferences for relevant trials.
We will also consider relevant for the review unpub-
lished and grey literature trials if we identify these.
Data collection and analysis
We will perform the review following the recommenda-
tions of the Cochrane Collaboration [79]. The analyses
will be performed using Review Manager 5 [83] and
Trial Sequential Analysis [84]. In case of Review Man-
ager statistical software not being sufficient, we will use
STATA 14 [85].
Selection of studies
Two authors (NJS and SS) will independently screen ti-
tles and abstracts. We will retrieve all relevant full-text
study reports/publications, and two review authors (NJS
and SS) will independently screen the full text and iden-
tify and record reasons for exclusion of the ineligible
studies. We will resolve any disagreement through dis-
cussion or, if required, we will consult a third person
(JCJ). Trial selection will be displayed in an adapted flow
diagram as per the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) state-
ment [86].
Data extraction and management
Four authors (NJS, SS, EEN, and JF) will in pairs extract
data independently from included trials. Disagreements
will be resolved by discussion with a fifth author (JCJ).
We will assess duplicate publications and companion
papers of a trial together to evaluate all available data
simultaneously (maximise data extraction, correct bias
assessment). We will contact the trial authors by email
to specify any additional data, which may not have been
reported sufficiently or at all in the publication.
Trial characteristics
Bias risk components (as defined below); trial design
(parallel, factorial, or crossover); number of intervention
arms; length of follow-up; estimation of sample size;
inclusion and exclusion criteria.
Participant characteristics and diagnosis
Number of randomised participants; number of analysed
participants; number of participants lost to follow-up/
withdrawals/crossover; compliance with medication; age
range (mean or median) and sex ratio; type of arrhythmia
(atrial fibrillation or atrial flutter); baseline numbers of
cardiovascular risk factors (i.e. diabetes mellitus, hyperten-
sion, hyperlipidaemia, or smoking); baseline number of
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participants with heart failure; baseline number of partici-
pants with valvular heart disease; baseline number of par-
ticipants with previous myocardial infarction; baseline
number of participants with previous revascularisation;
and baseline number of participants with previous angina.
We will additionally report the proportion of participants
in the compared groups who receive electrical cardiover-
sion, atrioventricular node ablation, catheter ablation, and
surgical ablation.
Rhythm control strategy characteristics
Type of rhythm control intervention, type of rate control
intervention, dose of intervention, duration of therapy,
and mode of administration.
Rate control strategy characteristics
Type of rate control intervention, dose of intervention,
duration of therapy, and mode of administration.
Co-intervention characteristics
Type of co-intervention; dose of co-intervention; dur-
ation of co-intervention; and mode of administration.
Outcomes
All outcomes listed above will be extracted from each
randomised clinical trial, and we will identify if out-
comes are incomplete or selectively reported according
to the criteria described later in ‘incomplete outcome
data’ bias domain and ‘selective outcome reporting’ bias
domain.
Notes
Funding of the trial and notable conflicts of interest of
trial authors will be extracted, if available.
We will note in the ‘Characteristics of included stud-
ies’ table if outcome data were not reported in a usable
way. Two review authors (NJS and SS) will independ-
ently transfer data into the Review Manager file [83].
Disagreements will be resolved through discussion or, if
required, we will consult with a third author (JCJ).
Assessment of risk of bias in included studies
We will use the instructions given in the Cochrane
Handbook for Systematic Reviews of Interventions [79]
in our evaluation of the methodology and hence the risk
of bias of the included trials. We will evaluate the meth-
odology in respect of:
 Random sequence generation
 Allocation concealment
 Blinding of participants and treatment providers
 Blinding of outcome assessment
 Incomplete outcome data
 Selective outcome reporting
 Other risks of bias
 Overall risk of bias
These components enable classification of randomised
trials with low risk of bias and high risk of bias. The
latter trials tend to overestimate positive intervention
effects and underestimate negative effects [87–93].
We will classify the trials according to the following
criteria.
Random sequence generation
 Low risk: If sequence generation was achieved using
computer random number generator or a random
number table. Drawing lots, tossing a coin, shuffling
cards, and throwing dice were also considered
adequate if performed by an independent
adjudicator.
 Unclear risk: If the method of randomisation was
not specified, but the trial was still presented as
being randomised.
 High risk: If the allocation sequence is not
randomised or only quasi-randomised. These trials
will be excluded.
Allocation concealment
 Low risk: If the allocation of patients was performed by
a central independent unit, on-site locked computer,
identical-looking numbered sealed envelopes, drug
bottles, or containers prepared by an independent
pharmacist or investigator.
 Uncertain risk: If the trial was classified as
randomised but the allocation concealment process
was not described.
 High risk: If the allocation sequence was familiar to
the investigators who assigned participants.
Blinding of participants and treatment providers
 Low risk: If the participants and the treatment
providers were blinded to intervention allocation
and this was described.
 Uncertain risk: If the procedure of blinding was
insufficiently described.
 High risk: If blinding of participants and the
treatment providers was not performed.
Blinding of outcome assessment
 Low risk of bias: If it was mentioned that outcome
assessors were blinded and this was described.
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 Uncertain risk of bias: If it was not mentioned if the
outcome assessors in the trial were blinded or the
extent of blinding was insufficiently described.
 High risk of bias: If no blinding or incomplete
blinding of outcome assessors was performed.
Incomplete outcome data
 Low risk of bias: If missing data were unlikely to
make treatment effects depart from plausible values.
This could be either (1) there were no drop-outs or
withdrawals for all outcomes or (2) the numbers and
reasons for the withdrawals and drop-outs for all
outcomes were clearly stated and could be described
as being similar to both groups. Generally, the trial
is judged as at a low risk of bias due to incomplete
outcome data if drop-outs are less than 5%.
However, the 5% cut-off is not definitive.
 Uncertain risk of bias: If there was insufficient
information to assess whether missing data were
likely to induce bias on the results.
 High risk of bias: If the results were likely to be
biased due to missing data either because the
pattern of drop-outs could be described as being
different in the two intervention groups or the trial
used improper methods in dealing with the missing
data (e.g. last observation carried forward).
Selective outcome reporting
 Low risk of bias: If a protocol was published before
or at the time the trial was begun and the outcomes
specified in the protocol were reported on. If there
is no protocol or the protocol was published after
the trial has begun, reporting of all-cause mortality
and serious adverse events will grant the trial a
grade of low risk of bias.
 Uncertain risk of bias: If no protocol was published
and the outcome all-cause mortality and serious
adverse events were not reported on.
 High risk of bias: If the outcomes in the protocol
were not reported on.
Other risks of bias
 Low risk of bias: If the trial appears to be free of
other components (for example, academic bias or
for-profit bias) that could put it at risk of bias.
 Unclear risk of bias: If the trial may or may not be
free of other components that could put it at risk of
bias.
 High risk of bias: If there are other factors in the
trial that could put it at risk of bias (for example,
authors conducted trials on the same topic, for-
profit bias, etc.).
Overall risk of bias
 Low risk of bias: The trial will be classified as overall
‘low risk of bias’ only if all of the bias domains
described in the above paragraphs are classified as
‘low risk of bias’.
 High risk of bias: The trial will be classified as ‘high
risk of bias’ if any of the bias risk domains described
in the above are classified as ‘unclear’ or ‘high risk of
bias’.
We will assess the domains ‘blinding of outcome as-
sessment’, ‘incomplete outcome data’, and ‘selective out-
come reporting’ for each outcome result. Thus, we can
assess the bias risk for each outcome assessed in
addition to each trial. Our primary conclusions will be
based on the results of our primary outcome results with
overall low risk of bias. Both our primary and secondary
conclusions will be presented in the summary of findings
tables.
Differences between the protocol and the review
We will conduct the review according to this published
protocol and report any deviations from it in the ‘Differ-
ences between the protocol and the review’ section of
the systematic review.
Measures of treatment effect
Dichotomous outcomes We will calculate risk ratios
(RRs) with 95% confidence interval (CI) for dichotomous
outcomes, as well as the Trial Sequential Analysis-
adjusted CIs (see below).
Continuous outcomes We will calculate the mean dif-
ferences (MDs) and the standardised mean difference
(SMD) with 95% CI for continuous outcomes, as well as
the Trial Sequential Analysis-adjusted CIs (see below).
Dealing with missing data
We will, as first option, contact all trial authors to obtain
any relevant missing data (i.e. for data extraction and for
assessment of risk of bias, as specified above).
Dichotomous outcomes We will not impute missing
values for any outcomes in our primary analysis. In two
of our sensitivity analyses (see paragraph below), we will
impute data.
Continuous outcomes We will primarily analyse scores
assessed at single time points. If only changes from
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baseline scores are reported, we will analyse the results
together with follow-up scores [79]. If standard devia-
tions (SDs) are not reported, we will calculate the SDs
using trial data, if possible. We will not use intention-to-
treat data if the original report did not contain such
data. We will not impute missing values for any out-
comes in our primary analysis. In our sensitivity analysis
(see paragraph below) for continuous outcomes, we will
impute data.
Assessment of heterogeneity
We will primarily investigate forest plots to visually
assess any sign of heterogeneity. We will secondly assess
the presence of statistical heterogeneity by chi2 test
(threshold P < 0.10) and measure the quantities of
heterogeneity by the I2 statistic [94, 95].
We will follow the recommendations for threshold by
the Cochrane Handbook for Systematic Reviews of Inter-
ventions [79]:
 0 to 40%: might not be important
 30 to 60%: may represent moderate heterogeneity
 50 to 90%: may represent substantial heterogeneity
 75 to 100%: may represent considerable
heterogeneity
We will investigate possible heterogeneity through
subgroup analyses. Ultimately, we may decide that a
meta-analysis should be avoided [79].
Assessment of reporting biases
We will use a funnel plot to assess reporting bias if ten
or more trials are included. We will visually inspect fun-
nel plots to assess the risk of bias. We are aware of the
limitations of a funnel plot (i.e. a funnel plot assesses
bias due to small sample size). From this information,
we assess possible reporting bias. For dichotomous out-
comes, we will test asymmetry with the Harbord test
[96] if τ2 is less than 0.1 and with the Rücker test if τ2 is
more than 0.1. For continuous outcomes, we will use the
regression asymmetry test [97] and the adjusted rank
correlation [98].
Unit of analysis issues We will only include rando-
mised clinical trials. For trials using crossover design,
only data from the first period will be included [79, 99].
There will therefore not be any unit of analysis issues.
We will not include cluster randomised trials.
Data synthesis
Meta-analysis We will undertake this meta-analysis ac-
cording to the recommendations stated in the Cochrane
Handbook for Systematic Reviews of Interventions [79],
Keus et al. [78], and the eight-step assessment suggested
by Jakobsen et al. [76]. We will use the statistical soft-
ware Review Manager 5.3 [83] provided by Cochrane to
analyse data.
We will assess our intervention effects with both
random-effects meta-analyses [100] and fixed-effects
meta-analyses [101]. We will use the more conservative
point estimate of the two [76]. The more conservative
point estimate is the estimate closest to zero effect. If
the two estimates are similar, we will use the estimate
with the widest CI. We use three primary outcomes, and
therefore, we will consider a P value of 0.025 or less as
the threshold for statistical significance [76]. We use two
secondary outcomes, and therefore, we will consider a P
value of 0.033 or less as threshold for statistical signifi-
cance [76, 102]. We will investigate possible heterogen-
eity through subgroup analyses. Ultimately, we may
decide that a meta-analysis should be avoided [79]. We
will use the eight-step procedure to assess if the thresh-
olds for significance are crossed [76]. Our primary con-
clusion will be based on results with low risk of bias
[76].
Where multiple trial arms are reported in a single trial,
we will include only the relevant arms. If two compari-
sons are combined in the same meta-analysis, we will
halve the control group to avoid double-counting [79].
Trials with a factorial design will be included. In case
of, e.g. a 2 × 2 factorial designed trial, the two groups re-
ceiving rhythm control interventions will be considered
rhythm control groups, while the two groups receiving
rate control interventions will be considered rate control
groups.
If quantitative synthesis is not appropriate, we will
report the results in a narrative way.
Trial Sequential Analysis Traditional meta-analysis
runs the risk of random errors due to sparse data and
repetitive testing of accumulating data when updating
reviews. We wish to control the risks of type I errors
and type II errors. We will therefore perform Trial Se-
quential Analysis on the outcomes, in order to calculate
the required information size (that is the number of par-
ticipants needed in a meta-analysis to detect or reject a
certain intervention effect) and the cumulative Z-curve’s
breach of relevant trial sequential monitoring boundaries
[77, 84, 103–110]. A more detailed description of Trial
Sequential Analysis can be found in the Trial Sequential
Analysis manual [108] and at http://www.ctu.dk/tsa/.
For dichotomous outcomes, we will estimate the
required information size based on the observed propor-
tion of patients with an outcome in the control group
(the cumulative proportion of patients with an event in
the control groups relative to all patients in the control
groups), a relative risk reduction of 15%, an alpha of
Sethi et al. Systematic Reviews  (2017) 6:47 Page 10 of 15
2.5% for our primary outcomes and an alpha of 3.3% for
our secondary outcomes, a beta of 10%, and diversity as
suggested by the trials in the meta-analysis. For continu-
ous outcomes, we will in the Trial Sequential Analysis use
the observed SD, a mean difference of the observed SD/2,
an alpha of 2.5% for our primary outcomes and an alpha
of 3.3% for our secondary outcomes, and a beta of 10%.
Subgroup analysis and investigation of heterogeneity
Subgroup analysis We will perform the following sub-
group analysis when analysing the primary outcomes
(all-cause mortality, serious adverse event, and quality of
life).
1. High risk of bias trials compared to low risk of bias
trials
2. Comparison of individual rhythm control
interventions with any rate control intervention
3. Comparison of individual rate control interventions
with any rhythm control intervention
4. Participants with atrial fibrillation compared to
participants with atrial flutter
5. Age of participants: 0 to 59 years, 60 to 79 years,
and above 80 years
6. Duration of atrial fibrillation: recent-onset atrial
fibrillation (as defined by the trialists), paroxysmal
atrial fibrillation (less than 7 days of onset),
persistent atrial fibrillation (more than 7 days and
less than 1 year of onset), and long-standing
persistent atrial fibrillation (more than 1 year of
onset)
7. Duration of anticoagulation therapy: anticoagulation
therapy until sinus rhythm for at least 4 weeks,
anticoagulation therapy until sinus rhythm for at
least 12 weeks, or anticoagulation therapy until end
of follow-up
8. Men compared to women
We will use the formal test for subgroup interactions in
Review Manager [83].
Sensitivity analysis To assess the potential impact of
the missing data for dichotomous outcomes, we will
perform the two following sensitivity analyses on both
the primary and secondary outcomes.
 ‘Best-worst-case’ scenario: We will assume that all
participants lost to follow-up in the rhythm control
group have survived, had no serious adverse event,
and had no stroke and that all those participants lost
to follow-up in the rate control group have not
survived, had a serious adverse event, and had a
stroke.
 ‘Worst-best-case’ scenario: We will assume that all
participants lost to follow-up in the rhythm control
group have not survived, had a serious adverse
event, and had a stroke and that all those
participants lost to follow-up in the rate control
group have survived, had no serious adverse event,
and had no stroke.
We will present results of both scenarios in our
review.
When analysing quality of life or ejection fraction, a
‘beneficial outcome’ will be the group mean plus two
standard deviations (SDs) (we will secondly use one SD
in another sensitivity analysis) of the group mean and a
‘harmful outcome’ will be the group mean minus two
SDs (we will secondly use one SD in another sensitivity
analysis) of the group mean [76].
To assess the potential impact of missing SDs for
continuous outcomes, we will perform the following
sensitivity analysis.
 Where SDs are missing and it is not possible to
calculate them, we will impute SDs from trials with
similar populations and low risk of bias. If we find
no such trials, we will impute SDs from trials with a
similar population. As the final option, we will
impute SDs from all trials.
We will present results of this scenario in our review.
Other post hoc sensitivity analyses might be warranted
if unexpected clinical or statistical heterogeneity is iden-
tified during the analysis of the review results [76].
‘Summary of Findings’ table We will create a Sum-
mary of Findings table using each of the prespecified
outcomes (all-cause mortality, serious adverse event,
quality of life, stroke, and ejection fraction). We will use
the five GRADE considerations (bias risk of the trials,
consistency of effect, imprecision, indirectness, and pub-
lication bias) to assess the quality of a body of evidence
as it relates to the studies which contribute data to the
meta-analyses for the prespecified outcomes [76, 111–
113]. We will use methods and recommendations de-
scribed in Chapter 8 (Section 8.5) and Chapter 12 of the
Cochrane Handbook for Systematic Reviews of Interven-
tions [79] using GRADEpro software. We will justify all
decisions to downgrade the quality of studies using
footnotes, and we will make comments to aid the
reader’s understanding of the review where necessary.
Firstly, we will present our results in the Summary of
Findings table based on the results from the trials
with low risk of bias, and secondly, we will present
the results based on all trials.
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Discussion
This protocol aims at comparing the effects of rhythm
control strategies with the effects of rate control strat-
egies in patients with atrial fibrillation and atrial flutter
to determine the best overall treatment strategy. The
outcomes will be all-cause mortality, serious adverse
events, quality of life, stroke, and ejection fraction.
This protocol has a number of strengths. The prede-
fined methodology is based on the Cochrane Handbook
for Systematic Reviews of Interventions [79], the eight-
step assessment suggested by Jakobsen et al. [76], Trial
Sequential Analysis [84], and GRADE assessment [111–
113]. Hence, this protocol takes into account both risks
of random errors and risks of systematic errors. Another
strength of this protocol is that we pragmatically com-
pare two overall treatment strategies with each other, i.e.
the results of this review will potentially reflect the
effects of the two strategies in clinical everyday practice.
Our protocol also has a number of limitations. The
primary limitation is that both of the strategies we com-
pare consist of multiple treatment elements and it is
likely that different interventions have different effects.
Hence, if we show a difference between the compared
strategies, it will be difficult to conclude what exactly
caused the difference in effect. To minimise this limita-
tion, a number of subgroups are planned, but results of
subgroup analyses should always be interpreted with
great caution. Another limitation is the large number of
comparisons which increase the risk of type 1 error. We
have adjusted our thresholds for significance according
to the number of primary outcomes, but, as mentioned,
we have also included multiple subgroup analyses. This
large risk of type 1 error will be taken into account when
interpreting the review results.
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